AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00975416 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Intranasal oxytocin given in the context of cognitive behavioral therapy
Study NCT00975416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Oxytocin
Description: Intranasal oxytocin given in the context of cognitive behavioral therapy
Study NCT00975416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given in the context of cognitive behavioral therapy
Study NCT00235807 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tinnitus Masking
Description: Sound therapy with Tinnitus Masking is intended to produce immediate relief from the discomfort caused by tinnitus (Vernon, 1977; 1987; Vernon, 1988). If maskers or combination units are used, the masking sound can be set at any level the patient chooses to attain maximum relief. Relief using masking noise can be accomplished using the external sound of the masker, which is generally a more acceptable sound than the tinnitus.
Study NCT00235807 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tinnitus Retraining Therapy (TRT)
Description: The TRT procedure adheres as closely as possible to the methodology described by Dr. Pawel Jastreboff. For TRT, sound therapy is used to facilitate long-term habituation to tinnitus (Jastreboff, 1999b).
Study NCT00235807 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tinnitus Education (TED)
Description: TED represents tinnitus treatment that would typically be provided by audiologists using hearing aids and counseling (although for this study the counseling has been structured and expanded to be equivalent in length to the other two groups).
Study NCT00697320 — intervention group
Intervention type: DRUG
Intervention: eptacog alfa (activated)
Description: A NON INTERVENTIONAL OBSERVATIONAL STUDY:~Doses and frequency of injections to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT02507076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isolated limb perfusion
Description: Undergo ILP with melphalan
Study NCT02507076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Undergo ILP with melphalan
Study NCT02507076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02365883 — intervention group
Intervention type: DEVICE
Intervention: Photoacoustic Imaging System
Description: manufactured by Endra
Study NCT01997125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural Bridge System
Description: Implanted device
Study NCT00937534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Fimasartan 240mg/day
Study NCT02143817 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline supplementation
Study NCT02143817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training
Description: The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 8 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
Study NCT00914121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-606
Study NCT00914121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00914121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study NCT00848016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-(-)-gossypol acetic acid
Description: Participants take 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Study NCT02222662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent massage tx group
Description: The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
Study NCT02222662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent massage wait-list control group
Description: The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
Study NCT01014234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporins
Description: These patients will undergo maintenance immunosuppressive treatment with cyclosporine + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
Study NCT01014234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: These patients will undergo maintenance immunosuppressive treatment with rapamycin + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
Study NCT03738735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: For the intervention group, the surgical staff will add 120 mL of 23.4% saline to the 3L bags of lactated Ringer's solution, and this new solution will be used for arthroscopic irrigation purposes throughout the rotator cuff repair surgery.
Study NCT01381120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate treatment
Description: Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months
Study NCT01381120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone and acetaminophen combination treatment
Description: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
Study NCT01381120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone and acetaminophen combination treatment
Description: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
Study NCT02944292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deepening of sedation
Description: Deepening of sedation will be achieved with a bolus and subsequent continuous infusion of propofol.
Study NCT02944292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be dosed according to lean body weight (LBW) for bolus administration and according to total body weight (TBW) for continuous infusion.~All patients will receive a bolus of propofol 1 mg/kg LBW as a rapid infusion during one minute. Measurements will be made one minute after the ending of bolus infusion. Continuous infusion of propofol at a rate of 3 mg/kg/h will be started immediately following completion of measurements, not later than 5 minutes after bolus administration. The propofol infusion rate is decreased in case of hemodynamic instability by 1 mg/kg/h and until a minimum of 1 mg/kg/h, if needed. Maximum total dose of infusion of 5 mg/kg/h will not be exceeded (bolus not considered).
Study NCT00743210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: Oral L-citrulline, 3 grams once per day for 3 weeks.
Study NCT00743210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 3 grams once per day for 3 weeks.
Study NCT03242785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-monitoring/Self-titration
Description: The intervention of the ADAMPA trial is not pharmacological but an intervention that modifies usual clinical practice. The intervention of self-monitoring and self-titration of the medication is composed of 3 elements:~1. Education of the patient: information and training on hypertension, its risks, management, the benefits of an adequate control and the generic measures for an optimal control.~2. Training for self-monitoring: Patients will be trained to perform the self-measurement of blood pressure correctly (and recording their values in the sheet enabled for this purpose)~3. Training for self-titration: patients will be instructed on the target BP numbers, individualized for each patient, on the mode of action against specific figures, including self-adjustment of drug treatment.
Study NCT04172740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse (calcium hydroxylpatite)
Description: RADIESSE® injectable implant is a sterile, non-pyrogenic, semi-solid, cohesive implant, whose principle component is synthetic calcium hydroxylapatite (CaHA) suspended in a gel carrier of sterile water for injection, glycerin and sodium carboxymethylcellulose. RADIESSE injectable implant has a CaHA particle size range of 25-45 microns. RADIESSE is available in 1.5cc and 0.8cc pre-filled syringes.~RADIESSE injectable implant is indicated for subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and it is also intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy).
Study NCT00473083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
Study NCT00473083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 2% in hydrocortisone 1% lotion
Description: Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.~If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles.
Study NCT00473083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be given on an outpatient basis at a fixed dose of either 150 or 100 mg as a single daily oral dose.
Study NCT00473083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
Description: Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water
Study NCT01723072 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Humanized monoclonal antibody against human IgE
Study NCT01723072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to omalizumab
Study NCT00689065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CALAA-01
Description: Subjects with solid tumors who satisfy the eligibility criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four (4) 30-minute intravenous infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered consisting of infusions on days 22, 24, 29 and 31 followed by 11 days of rest.
Study NCT00635505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol HFA (Armstrong's)
Description: 180 mcg QID 12 weeks
Study NCT00635505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol HFA (Proventil HFA)
Description: 180 mcg QID 12 weeks
Study NCT00635505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HFA placebo
Description: 2 actuations QID 12 weeks or until use of rescue drug
Study NCT01562899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Supplied as tablets of dosage strength 15 mg in high-density polyethylene bottles with child-resistant closure.
Study NCT01562899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: Supplied as sterile liquid for intravenous infusion in vials in boxes. Until April 2013 a frozen formulation with a concentration of 30 mg/ml was used; from May 2013 onwards a refrigerated formulation with a concentration of 70 mg/ml was used.
Study NCT00880126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Development Teams
Description: CDTs bring together counties who are implementing a new practice
Study NCT04271215 — intervention group
Intervention type: OTHER
Intervention: Chemotherapy protocol used
Description: Chemotherapy protocol used in each participating hospital
Study NCT00855348 — intervention group
Intervention type: OTHER
Intervention: All eligible subjects will provide blood for SEPT9 biomarker testing
Description: A single blood sample per participant selected according to analysis plan is tested for evidence of methylation of a specific DNA sequence, SEPT9.
Study NCT03337126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Tablet
Description: Comparator Drug
Study NCT02118623 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderated discussion board
Description: All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone.~The discussion boards will be moderated by research staff, who will be supervised by a trained clinician (masters levels or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group.
Study NCT02118623 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:~1. What is bipolar disorder? - Content about symptoms and diagnosis~2. Stress and triggers of illness~3. Medication and the biological basis of bipolar disorder~4. Depression - Symptoms, early detection and helpful strategies~5. Mania and hypomania - Symptoms, early detection and helpful strategies.
Study NCT02118623 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Psychosocial Tools
Description: Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviours, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan.
Study NCT03363906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide (Reference)
Description: Administered SC
Study NCT03363906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide (Test)
Description: Administered SC
Study NCT05531877 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Penile Prosthesis Implantation
Description: Penile measurement are taken preoperatively to serve as a guide to the surgeon to optimize post-operative penile size.
Study NCT00492297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)
Description: Dacarbazine 1000 mg/m\^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
Study NCT00888654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-Dim
Description: B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Study NCT00888654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prosatectomy
Study NCT03287765 — intervention group
Intervention type: DRUG
Intervention: 18F-AV-1451
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study NCT01524315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B1-ratiopharm
Description: 300 mg Thiaminchloridhydrochlorid, once, intravenous, preoperative
Study NCT01524315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml normal saline, intravenous, preoperative
Study NCT00012116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
Study NCT02891512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ELF
Description: Very low frequency magnetic fields (ELF) at intensity of 100 mT and a frequency of 1-80 Hz. Protocol (antiedema-antinflammatory): 12 sessions, 3 times a week for 4 consecutive weeks, each session lasted 30 minutes.
Study NCT02891512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELF
Description: Very low frequency magnetic fields (ELF) at intensity of 100 mT and a frequency of 1-80 Hz. Protocol (antiedema-antinflammatory): 12 sessions, 3 times a week for 4 consecutive weeks, each session lasted 30 minutes.
Study NCT02891512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xinepa®
Description: 2 tablets of Xinepa daily (morning and evening) for 1 month.
Study NCT02891512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Xinepa®
Description: 2 tablets of Xinepa placebo daily (morning and evening) for 1 month.
Study NCT03455608 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RE-ACTIVE
Description: Reactive intervention started promptly if/when dysphagia is identified
Study NCT03455608 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRO-ACTIVE EAT
Description: Early low intensity proactive intervention started before RT commences
Study NCT03455608 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRO-ACTIVE EAT + EXERCISE
Description: Early high intensity proactive intervention started before RT commences
Study NCT03226444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.005% Lacripep
Description: One drop (approximately 50 microliters) of 0.005% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
Study NCT03226444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% Lacripep
Description: One drop (approximately 50 microliters) of 0.01% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
Study NCT03226444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop (approximately 50 microliters) of placebo solution will be administered three times a day (TID) to both eyes for four weeks.
Study NCT01472055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 1. Fludarabine 40 mg/m\^2 once a day intravenous administration over 30 min~2. Development of sampling-minimized analysis method through individualized pharmacokinetics Sampling time: 0hr (pre-dose), 30 min (post-dose), 1hr, 3hr, 5hr, 8hr, 24hr~3. Population pharmacokinetics analysis~4. Comparative analysis of population pharmacokinetics in pediatric and adult patients~5. Analysis of population pharmacokinetics, toxicity, engraftment rate, survival rate
Study NCT03313739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An Educational Program
Description: An educational program was designed for self-care during menopause using teach back method.
Study NCT03129932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: gluten phase
Description: 2 cakes containing 9g of vital gluten/each will be consume during the 4 weeks of intervention
Study NCT03129932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo phase
Description: 2 cakes without gluten will be consume during the 4 weeks of intervention
Study NCT01795443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calibration
Description: Subjects will be seated on a table, feet dangling, blindfolded, arms crossed over the chest and held in place by bandages to minimize the visual and proprioceptive inputs that may contribute to the realization of the task.~The investigator uses an electronic goniometer to measure the maximal extension and flexion during a pelvic pivot. These measures will be used to determine a target position midway along the pelvic movement range.